FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386704012> ?p ?o ?g. }

• W4386704012 abstract "Abstract Objectives This post hoc pooled analysis evaluated clinical and microbiological outcomes and safety in patients with infections caused by β-lactamase-producing Gram-negative pathogens across five Phase 3, randomized, controlled, multicentre trials of ceftazidime/avibactam in adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI)/pyelonephritis and nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP). Methods In each trial, RECLAIM/RECLAIM 3 (cIAI), REPRISE (cIAI/cUTI), RECAPTURE (cUTI) and REPROVE (NP, including VAP) patients were randomized 1:1 to IV ceftazidime/avibactam (plus metronidazole for patients with cIAI) or comparators (carbapenems in &gt;97% patients) for 5–21 days. Clinical and microbiological responses at the test-of-cure visit were assessed for patients with ESBLs, and/or plasmidic and/or overexpression of chromosomal AmpC, and/or serine carbapenemases without MBLs identified in baseline Gram-negative isolates by phenotypic screening and molecular characterization in the pooled microbiological modified ITT (mMITT) population. Results In total, 813 patients (ceftazidime/avibactam, n = 389; comparator, n = 424) had ≥1 β-lactamase-producing baseline pathogen identified, amongst whom 792 patients (ceftazidime/avibactam, n = 379; comparator, n = 413) had no MBLs. The most frequent β-lactamase-producing pathogens across treatment groups were Escherichia coli (n = 381), Klebsiella pneumoniae (n = 261) and Pseudomonas aeruginosa (n = 53). Clinical cure rates in the pooled non-MBL β-lactamase-producing mMITT population were 88.1% (334/379) for ceftazidime/avibactam and 88.1% (364/413) for comparators; favourable microbiological response rates were 76.5% (290/379) and 68.8% (284/413), respectively. The safety profile of ceftazidime/avibactam was consistent with previous observations. Conclusions This analysis provides supportive evidence of the efficacy and safety of ceftazidime/avibactam in patients with infections caused by ESBLs, AmpC and serine carbapenemase-producing Gram-negative pathogens. Trial registration NCT01499290; NCT01726023; NCT01644643; NCT01595438/NCT01599806; NCT01808092." @default.
• W4386704012 created "2023-09-14" @default.
• W4386704012 creator A5018936151 @default.
• W4386704012 creator A5020992600 @default.
• W4386704012 creator A5021332807 @default.
• W4386704012 creator A5026604447 @default.
• W4386704012 creator A5058226005 @default.
• W4386704012 creator A5064433248 @default.
• W4386704012 creator A5071962316 @default.
• W4386704012 creator A5074358267 @default.
• W4386704012 creator A5075544791 @default.
• W4386704012 creator A5089858392 @default.
• W4386704012 date "2023-09-13" @default.
• W4386704012 modified "2023-09-26" @default.
• W4386704012 title "Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme" @default.
• W4386704012 cites W1986439495 @default.
• W4386704012 cites W2098693822 @default.
• W4386704012 cites W2099001508 @default.
• W4386704012 cites W2106298631 @default.
• W4386704012 cites W2106578604 @default.
• W4386704012 cites W2124945254 @default.
• W4386704012 cites W2131946678 @default.
• W4386704012 cites W2137202092 @default.
• W4386704012 cites W2143046682 @default.
• W4386704012 cites W2149315953 @default.
• W4386704012 cites W2155027656 @default.
• W4386704012 cites W2158444827 @default.
• W4386704012 cites W2168409658 @default.
• W4386704012 cites W2289006193 @default.
• W4386704012 cites W2294833633 @default.
• W4386704012 cites W2339819000 @default.
• W4386704012 cites W2345728091 @default.
• W4386704012 cites W2437593726 @default.
• W4386704012 cites W2473016454 @default.
• W4386704012 cites W2528498234 @default.
• W4386704012 cites W2549454559 @default.
• W4386704012 cites W2602847039 @default.
• W4386704012 cites W2619325951 @default.
• W4386704012 cites W2729161724 @default.
• W4386704012 cites W2773548512 @default.
• W4386704012 cites W2786886659 @default.
• W4386704012 cites W2793495265 @default.
• W4386704012 cites W2799368848 @default.
• W4386704012 cites W2803965271 @default.
• W4386704012 cites W2809662916 @default.
• W4386704012 cites W2884336796 @default.
• W4386704012 cites W2884524290 @default.
• W4386704012 cites W2892368225 @default.
• W4386704012 cites W2898144230 @default.
• W4386704012 cites W2944808759 @default.
• W4386704012 cites W2975920332 @default.
• W4386704012 cites W2987425231 @default.
• W4386704012 cites W3015425125 @default.
• W4386704012 cites W3019276013 @default.
• W4386704012 cites W3034079270 @default.
• W4386704012 cites W3038933864 @default.
• W4386704012 cites W3091854646 @default.
• W4386704012 cites W3092173712 @default.
• W4386704012 cites W3092383626 @default.
• W4386704012 cites W3096754926 @default.
• W4386704012 cites W3154328754 @default.
• W4386704012 cites W3175135562 @default.
• W4386704012 cites W3192067479 @default.
• W4386704012 cites W4214677785 @default.
• W4386704012 cites W4224266833 @default.
• W4386704012 doi "https://doi.org/10.1093/jac/dkad280" @default.
• W4386704012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37700689" @default.
• W4386704012 hasPublicationYear "2023" @default.
• W4386704012 type Work @default.
• W4386704012 citedByCount "0" @default.
• W4386704012 crossrefType "journal-article" @default.
• W4386704012 hasAuthorship W4386704012A5018936151 @default.
• W4386704012 hasAuthorship W4386704012A5020992600 @default.
• W4386704012 hasAuthorship W4386704012A5021332807 @default.
• W4386704012 hasAuthorship W4386704012A5026604447 @default.
• W4386704012 hasAuthorship W4386704012A5058226005 @default.
• W4386704012 hasAuthorship W4386704012A5064433248 @default.
• W4386704012 hasAuthorship W4386704012A5071962316 @default.
• W4386704012 hasAuthorship W4386704012A5074358267 @default.
• W4386704012 hasAuthorship W4386704012A5075544791 @default.
• W4386704012 hasAuthorship W4386704012A5089858392 @default.
• W4386704012 hasConcept C104317684 @default.
• W4386704012 hasConcept C126322002 @default.
• W4386704012 hasConcept C2775933652 @default.
• W4386704012 hasConcept C2776933286 @default.
• W4386704012 hasConcept C2776968632 @default.
• W4386704012 hasConcept C2777058267 @default.
• W4386704012 hasConcept C2777406300 @default.
• W4386704012 hasConcept C2777637488 @default.
• W4386704012 hasConcept C2777914695 @default.
• W4386704012 hasConcept C2908647359 @default.
• W4386704012 hasConcept C523546767 @default.
• W4386704012 hasConcept C54355233 @default.
• W4386704012 hasConcept C547475151 @default.
• W4386704012 hasConcept C55493867 @default.
• W4386704012 hasConcept C71924100 @default.
• W4386704012 hasConcept C86803240 @default.
• W4386704012 hasConcept C89423630 @default.
• W4386704012 hasConcept C99454951 @default.
• W4386704012 hasConceptScore W4386704012C104317684 @default.

• next